Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFFRON: savolitinib + osimertinib versus platinum-pemetrexed chemotherapy in EGFR-mutant, MET-positive advanced non-small cell lung cancer after progression on osimertinib
MOH_2022-07-19_010822Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of savolitinib and osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Jul 2022; status: recruiting.
02
Drugs
savolitinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2022-07-19_010822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-07-19_010822.